During the period 1984-88 several hundred samples of meat, liver and kidney from Swedish pigs and cattle were analysed for lead, cadmium, arsenic and mercury. Analysis was performed by AAS and extensive quality assurance was carried out. The mean lead levels in pig meat, liver and kidney were less than 0.005, 0.019 and 0.016 mg/kg, respectively: the mean levels in the corresponding bovine tissues were less than 0.005, 0.047 and 0.097 mg/kg. The mean cadmium levels in pig meat, liver and kidney were 0.001, 0.019 and 0.11 mg/kg, whilst those in the corresponding bovine tissues were 0.001, 0.070 and 0.39 mg/kg. The mean arsenic levels in pig meat, liver and kidney were 0.024, 0.023 and 0.019, respectively and those in the corresponding bovine tissues were lower, none exceeding 0.015 mg/kg. The mean mercury levels in pig meat, liver and kidney were 0.009, 0.015 and 0.019 mg/kg respectively, while those in the corresponding bovine tissues were 0.005, 0.006 and 0.010 mg/kg. A decrease in the levels of both arsenic and mercury in pig tissues was found during the period studied, which may be due to a decrease in the use of fish meal in pig feed.

Abattoirs↗

PubMedDate not supplied

Supplementation of omega-3 fatty acids in patients with ankylosing spondylitis.

OBJECTIVE: To study the effect of supplementation with omega-3 fatty acids on disease variables and drug consumption in patients with ankylosing spondylitis (AS). METHODS: Twenty-four patients were randomized to either a low-dose (1.95 g omega-3/day) or a high-dose (4.55 g omega-3/day) supplement. Disease activity, functional impairment, erythrocyte sedimentation rate (ESR), and drug consumption were assessed during visits at baseline and at weeks 7, 14, and 21. RESULTS: Eighteen patients completed the study, nine patients from each group. The patients in the high-dose group exhibited a significant decrease in disease activity according to the Bath Ankylosing Disease Activity Index (BASDAI; p = 0.038), which was not seen in the low-dose group. Significant differences were not found on drug consumption or in functional capacity in either of the groups. No significant differences were found when comparing the results between the high- and low-dose groups. CONCLUSION: Omega-3 fatty acids in adequate doses may have the capacity to decrease the disease activity of AS. However, larger and better controlled studies are needed before any further conclusions can be made on the extent of this capacity.

Adolescent↗

PubMedDate not supplied

Cadmium and other metals in Swedish wheat and rye flours: longitudinal study, 1983-1997.

Wheat flour (sifted), wheat bran, and rye flour were sampled annually in several different areas in Sweden for 15 consecutive years (1983-1997) for a total of 105, 90, and 30 samples, respectively. These samples were analyzed for their content of Cd, Co, Cr, Cu, Fe, Mn, Ni, Pb, and Zn by atomic absorption spectrophotometry with background correction after dry ashing at 450 degrees C. As part of the quality control procedures, an in-house reference material was analyzed in parallel to the samples to ensure reliability of the results. In addition, a certified reference material was analyzed to monitor accuracy of the results. The Cd level in wheat and rye flours (mean 0.029 and 0.017 mg/kg dry wt, respectively) correlated significantly with time (p < 0.05) in 2 phases, tending to increase during the first half of the period and decrease during the latter half. In wheat bran, Cd (mean 0.15 mg/kg) levels did not correlate significantly with time. In wheat flour, Cu, Mn, and Zn (means 1.7, 6.2, and 7.6 mg/kg, respectively) showed a significant linear increase (p < 0.05) in concentration over time. In rye flour, the levels of Cu, Fe, Mn, and Zn (means 3.8, 36, 30, and 28 mg/kg, respectively) all decreased significantly (p < 0.05) over time. Similarly, in wheat bran Cu (mean 14 mg/kg) increased and Pb (mean 0.027 mg/kg) decreased significantly (p < 0.05) over time, whereas Ni and Zn showed a significant curved correlation with time and peaked at about the middle of the measurement period.

Cadmium↗

PubMedDate not supplied

Inhibition of growth of HeLa cell tumours in nude mice by 125I-labeled anticytokeratin and antiPLAP monoclonal antibodies.

The radiommunotherapeutic potential of 125I-labeled monoclonal antibodies was investigated in 48 nude mice (BALB/c, nu/nu) inoculated s.c. with the HeLa Hep 2 human adenocarcinoma cell line. This isotope, 125I, which is not commonly used for therapeutic purposes caused significant decrease in tumour growth from day 10 to day 42, when coupled to monoclonal antibodies directed against placental alkaline phosphatase (H7) or cytokeratins (TS1). The average growth rate was approximately 50-60% of that observed in the untreated control group after 42 days. The specific radioactivity in each organ 42 days after injection of radiolabeled monoclonal antibodies, indicated that these target antigens retain significant amounts of radiolabeled antibody in the tumours for at least 6 weeks after injection. No weight loss was seen in the animals during this experiment. By use of autoradiographic techniques, the labeled monoclonal antibodies were visualized deep in tumours in characteristic patterns representative of viable tumour cells (H7) and necrotic areas (TS1). The therapeutic approach using 125I labeled antibodies is encouraging and may offer new dimensions in radioimmunotherapy.

Adenocarcinoma↗